Skip to main content
Clinical Trials/ISRCTN10001405
ISRCTN10001405
Active, not recruiting
未知

Prospective Evaluation of AI R&D tool for patient stratification - Trial for Renal immuno-oncology model Experimental Evaluation (PEAR-TREE)

Ourotech Limited (trading as Pear Bio)0 sites20 target enrollmentOctober 14, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Patients undergoing surgery for renal cell carcinoma
Sponsor
Ourotech Limited (trading as Pear Bio)
Enrollment
20
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 14, 2022
End Date
March 31, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Ourotech Limited (trading as Pear Bio)

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged 18 years old and over
  • 2\. Patients with operable kidney cancer
  • 3\. Able to give informed consent
  • 4\. Able to give 40 ml of blood and surgical sample yields \>\= 0\.4 g of cancerous tissue

Exclusion Criteria

  • 1\. Inoperable or metastatic kidney cancer
  • 2\. Pre\-operative haemoglobin levels below 120g/l
  • 3\. Patients who have already commenced chemotherapy, targeted therapy, immunotherapy or radiotherapy
  • 4\. Recurrence of cancer from any other site than the kidney
  • 5\. Any other disease or finding that renders the patient at high risk of treatment complications or interferes with obtaining informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials